Floatz logo

Carboplatin

Progesterone Receptor Negative

Northwestern UniversitySmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Progesterone Receptor Negative cohort.

Asset / SponsorPhaseRating
Epirubicin
Massachusetts General Hospital
Phase 2BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →